| Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2023: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2022: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2021: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2020: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2019: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Outline of Final Research Achievements |
Although there is no established treatment for glaucoma, a treatment that improves visual function by encapsulating neurotrophic factor-producing cells in a device and implanting it in the eye is being investigated in the United States. In this study, we examined the efficacy and safety of this treatment in an international collaboration with Professor Goldberg, who is leading this treatment. In the final year of the project, we held a glaucoma symposium at Stanford University to share the progress of our research. We also found that it is possible to suppress cell death by gene therapy in glaucoma models by modifying the brain-derived neurotrophic factor receptor to its constitutively active form. As mentioned above, we have gained many useful insights through our collaborative research.
|
